Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Marchand

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|August 5, 2016
Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA)Zhe Li Salie, Karen A Kirby, Eleftherios Michailidis, et al.
Hepatology Communications|June 23, 2022
Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosisArchana Vijayakumar, Ayse Okesli-Armlovich, Ting Wang, et al.
The Journal of Biological Chemistry|October 20, 2009
Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitorEleftherios Michailidis, Bruno Marchand, Eiichi N Kodama, et al.
Antimicrobial Agents and Chemotherapy|June 26, 2013
Evaluation of Combinations of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Clinically Used Antiretroviral DrugsAtsuko Hachiya, Aaron B Reeve, Bruno Marchand, et al.
Journal of Virology|June 7, 2019
Hepatitis B Virus X Protein Function Requires Zinc BindingDhivya Ramakrishnan, Weimei Xing, Rudolf K Beran, et al.
The Journal of Biological Chemistry|July 5, 2012
HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitorsAtsuko Hachiya, Bruno Marchand, Karen A Kirby, et al.
Retrovirology|June 27, 2013
Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdAEleftherios Michailidis, Emily M Ryan, Atsuko Hachiya, et al.
Antimicrobial Agents and Chemotherapy|January 19, 2012
Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptaseKaren A Kirby, Bruno Marchand, Yee Tsuey Ong, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 30, 2014
Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247Karen A Kirby, Yee Tsuey Ong, Atsuko Hachiya, et al.
Antimicrobial Agents and Chemotherapy|October 9, 2013
Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosineKaren A Kirby, Eleftherios Michailidis, Tracy L Fetterly, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Proceedings of the National Academy of Sciences of the United States of America|August 5, 2016
Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA)Zhe Li Salie, Karen A Kirby, Eleftherios Michailidis, et al.
Hepatology Communications|June 23, 2022
Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosisArchana Vijayakumar, Ayse Okesli-Armlovich, Ting Wang, et al.
The Journal of Biological Chemistry|October 20, 2009
Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitorEleftherios Michailidis, Bruno Marchand, Eiichi N Kodama, et al.
Antimicrobial Agents and Chemotherapy|June 26, 2013
Evaluation of Combinations of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Clinically Used Antiretroviral DrugsAtsuko Hachiya, Aaron B Reeve, Bruno Marchand, et al.
Journal of Virology|June 7, 2019
Hepatitis B Virus X Protein Function Requires Zinc BindingDhivya Ramakrishnan, Weimei Xing, Rudolf K Beran, et al.
The Journal of Biological Chemistry|July 5, 2012
HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitorsAtsuko Hachiya, Bruno Marchand, Karen A Kirby, et al.
Retrovirology|June 27, 2013
Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdAEleftherios Michailidis, Emily M Ryan, Atsuko Hachiya, et al.
Antimicrobial Agents and Chemotherapy|January 19, 2012
Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptaseKaren A Kirby, Bruno Marchand, Yee Tsuey Ong, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 30, 2014
Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247Karen A Kirby, Yee Tsuey Ong, Atsuko Hachiya, et al.
Antimicrobial Agents and Chemotherapy|October 9, 2013
Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosineKaren A Kirby, Eleftherios Michailidis, Tracy L Fetterly, et al.
Pageof 4